Company news
Vaxcyte, Inc. news in 2024
Vaxcyte, Inc.'s news releases, calls and decks from 2024, newest first.
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
December 2, 2024
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
November 11, 2024
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
November 4, 2024
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 5, 2024
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
September 3, 2024
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 2, 2024
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 1, 2024
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
August 5, 2024
Vaxcyte Appoints John Furey to Board of Directors
July 1, 2024
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
May 7, 2024
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 1, 2024
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
March 3, 2024
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 26, 2024
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 14, 2024
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 1, 2024
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
January 31, 2024
Vaxcyte Announces Pricing of $750 Million Public Offering
January 29, 2024
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
January 28, 2024
Vaxcyte Appoints Whitney Jones as Chief People Officer
January 15, 2024
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
January 3, 2024
Calls in 2024
Decks in 2024
- Technical Presentation (September 2024)
Technical · 34 slides · Sep 3, 2024